During summer time in Colorado it seems like there is a different 5K every weekend!...
On May 26-27, 2015, the Rocky Mountain Colorectal Cancer Summit will be held in Denver...
Oral milk thistle extract stops colorectal cancer stem cells from growing tumors
April 20, 2015 · Comments Off on Oral milk thistle extract stops colorectal cancer stem cells from growing tumors
Results presented at AACR 2015 show that orally administering the chemical silibinin, purified from milk thistle, slows the ability of colorectal cancer stem cells to grow the disease.
Colorectal Cancer Survivor Honors Friends and Continues Awareness Work
January 22, 2015 · Comments Off on Colorectal Cancer Survivor Honors Friends and Continues Awareness Work
By: Joelle Klein When I first met Karen Wehling, Joan Ponds, and Linda Woltkamp last...
One-Two Punch of Drugs Better Than Either Alone Against Colorectal Cancer
November 25, 2014 · Comments Off on One-Two Punch of Drugs Better Than Either Alone Against Colorectal Cancer
CU lab study and clinical trial target two of the most commonly mutated gene signaling pathways in cancer, at the same time.
Milk Thistle Extract, Silibinin, Reduces Self-Renewal of Colorectal Cancer Stem Cells
April 7, 2014 · Comments Off on Milk Thistle Extract, Silibinin, Reduces Self-Renewal of Colorectal Cancer Stem Cells
A University of Colorado Cancer Center study presented today at the American Association for Cancer Research (AACR) Annual Meeting 2014 shows that the chemical silibinin, purified from milk thistle extract, affects cell signaling associated with inflammation and thus also the formation and survival of colorectal cancer stem cells.
Study finds known lung cancer oncogenes ALK and ROS1 also drive colorectal cancer
December 17, 2013 · Comments Off on Study finds known lung cancer oncogenes ALK and ROS1 also drive colorectal cancer
Study shows that shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients.
Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)
October 28, 2013 · Comments Off on Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)
A University of Colorado Cancer Center study published in the journal PLoS One shows that, like overflowing a dam, colorectal cancer may resist the drug bevacizumab (Avastin), by switching dependence from the main flow of VEGF-A to the "tributaries" of related growth factors including VEGF-C, VEGF-D and placental growth factor.
Dietary supplements shown to increase cancer risk
October 28, 2013
Bitter melon juice prevents pancreatic cancer in mouse models
October 28, 2013
AACR amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno ASCO biomarkers bladder cancer breast cancer cancer cancer grants cancer prevention cancer research colorado Cancer Survivorship clinical trial colon cancer colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma ovarian cancer Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge skin cancer tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
We are on our way to #ASCO15!! Stay tuned for updates!